TopFunds

Amgen Inc.

NASDAQ: AMGN

Stock price

432.49 USD

(+0%) TODAY

Drug Manufacturers - General
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
9.1
10.2
2.7
12.6
12.9
12.3
10.3
12.1
12.5
7.6
14.2
4.6%
02Free cash flow per share
11
12.6
14.3
15.9
14
16.8
14.6
16.2
13.7
19.2
14.9
3.1%
03Dividends per share
3.2
4
4.6
5.3
5.8
6.4
7
7.8
8.5
9
9.5
11.7%
04Dividends payout, %
34.5%
38.8%
1.7%
41.8%
44.8%
51.7%
68.1%
64%
67.8%
1.2%
66.5%
6.8%
PROFIT AND LOSS STATEMENT
05Revenue
21,662
22,991
22,849
23,747
23,362
25,424
25,979
26,323
28,190
33,424
36,741
5.4%
06% Change
-
-
-
-
-
-
-
-
-
-
-
5.4%
07Cost of revenue
(4,227)
(4,162)
(4,069)
(4,101)
(4,356)
(6,159)
(6,454)
(6,406)
(8,415)
(12,858)
(10,729)
9.8%
08Gross profit
17,435
18,829
18,780
19,646
19,006
19,265
19,525
19,917
19,775
20,566
26,012
4.1%
09% Margin
80.5%
81.9%
82.2%
82.7%
81.4%
75.8%
75.2%
75.7%
70.2%
61.5%
70.8%
76.2% A
10Operating expenses
(8,965)
(9,035)
(8,807)
(9,383)
(9,332)
(10,126)
(11,886)
(10,351)
(11,842)
(13,308)
(15,336)
5.5%
11% of Revenue
(41.4)%
(39.3)%
(38.5)%
(39.5)%
(40)%
(39.8)%
(45.8)%
(39.3)%
(42)%
(39.8)%
(41.7)%
(40.7)% A
12Operating Income
8,470
9,794
9,973
10,263
9,674
9,139
7,639
9,566
7,897
7,258
10,676
2.3%
13Income tax expense
(1,039)
(1,441)
(7,618)
(1,151)
(1,296)
(869)
(808)
(794)
(1,138)
(519)
(1,265)
2%
14Net Income
6,939
7,722
1,979
8,394
7,842
7,264
5,893
6,552
6,717
4,090
7,711
1.1%
15% Margin
32%
33.6%
8.7%
35.4%
33.6%
28.6%
22.7%
24.9%
23.8%
12.2%
21%
25.1% A
16Shares Outstanding
766
754
735
665
609
590
573
541
538
541
542
(3.4)%
17EPS Basic
9.2
10.3
2.7
12.7
13
12.4
10.3
12.2
12.6
7.6
14.3
4.6%
18EPS Diluted
9.1
10.2
2.7
12.6
12.9
12.3
10.3
12.1
12.5
7.6
14.2
4.6%
19EBITDA
11,181
12,528
12,856
12,883
12,633
12,996
11,296
12,169
14,801
13,356
16,898
4.2%
% Margin
51.6%
54.5%
56.3%
54.3%
54.1%
51.1%
43.5%
46.2%
52.5%
40%
46%
50% A
20Net Interest Income (expense)
(492)
(631)
(376)
(718)
(702)
(1,262)
(1,197)
(1,406)
(2,875)
(3,155)
(2,755)
18.8%
21Net Debt / EBITDA
2.4
2.5
2.5
2.1
1.9
2.1
2.2
2.6
3.6
3.6
2.7
2.6 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
4,144
3,241
3,800
6,945
6,037
6,266
7,989
7,629
10,944
11,973
9,129
8.2%
23Short-term investments
27,238
34,844
37,878
22,359
2,874
4,381
48
1,676
-
-
-
-
24Accounts receivable
2,995
3,165
3,237
3,580
4,057
4,525
5,839
6,392
7,942
7,501
9,570
12.3%
25Other current assets
1,703
2,015
1,727
1,794
1,888
2,079
1,423
1,559
1,928
2,558
4,133
9.3%
26Inventory
2,435
2,745
2,834
2,940
3,584
3,893
4,086
4,930
9,518
6,998
6,225
9.8%
27Total Current Assets
38,515
46,010
49,476
37,618
18,440
21,144
19,385
22,186
30,332
29,030
29,057
(2.8)%
Non-Current Assets
28Net property, plant & equipment
4,907
4,961
4,989
4,958
4,928
4,889
5,184
5,427
5,941
6,543
8,515
5.7%
29Long-term investments
-
-
-
-
-
-
-
-
4,711
5,355
6,804
-
30Other non-current assets
28,027
26,655
25,489
23,840
36,339
36,915
36,596
37,508
56,170
50,911
46,210
5.1%
31Total Non-Current Assets
32,934
31,616
30,478
28,798
41,267
41,804
41,780
42,935
66,822
62,809
61,529
6.5%
Total Assets
71,576
77,626
79,954
66,416
59,707
62,948
61,165
65,121
97,154
91,839
90,586
2.4%
LIABILITIES
Current Liabilities
32Accounts payable
965
917
1,352
1,207
1,371
1,421
1,366
1,572
1,590
1,908
2,367
9.4%
33Short-term debt
2,247
4,403
1,152
4,419
2,953
91
87
1,591
1,443
3,550
4,599
7.4%
34Other current liabilities
5,452
5,884
6,516
7,862
8,511
10,141
10,731
12,524
15,359
17,641
18,523
13%
35Total Current Liabilities
8,664
11,204
9,020
13,488
12,835
11,653
12,184
15,687
18,392
23,099
25,489
11.4%
Non-Current Liabilities
36Long-term debt
29,182
30,193
34,190
29,510
26,950
32,895
33,222
37,354
63,170
56,549
50,005
5.5%
37Other non-current liabilities
5,520
6,354
11,503
10,918
10,249
8,991
9,059
8,419
9,360
6,314
6,434
1.5%
38Total Non-Current Liabilities
34,702
36,547
45,693
40,428
37,199
41,886
42,281
45,773
72,530
62,863
56,439
5%
39Total Liabilities
43,366
47,751
54,713
53,916
50,034
53,539
54,465
61,460
90,922
85,962
81,928
6.6%
SHAREHOLDERS` EQUITY
40Common stock
30,649
30,784
30,992
31,246
31,531
31,802
32,096
32,514
33,070
33,533
34,023
1.1%
41Retained earnings / (deficit)
(2,086)
(438)
(5,072)
(17,977)
(21,330)
(21,408)
(24,600)
(28,622)
(26,549)
(27,590)
(25,107)
28.3%
42Accumulated other comprehensive income / (loss)
(480)
(471)
(679)
(769)
(528)
(985)
(796)
(231)
(289)
(66)
(258)
(6)%
43Noncontrolling interests
-
-
-
-
-
-
-
-
-
-
-
-
44Total shareholders' equity
28,083
29,875
25,241
12,500
9,673
9,409
6,700
3,661
6,232
5,877
8,658
(11.1)%
45Total Liabilities and shareholders' Equity
71,449
77,626
79,954
66,416
59,707
62,948
61,165
65,121
97,154
91,839
90,586
2.4%
46Total Debt
31,429
34,596
35,342
33,929
29,903
32,986
33,309
38,945
64,613
60,099
54,604
5.7%
47Net Debt
27,285
31,355
31,542
26,984
23,866
26,720
25,320
31,316
53,669
48,126
45,475
5.2%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
6,939
7,722
1,979
8,394
7,842
7,264
5,893
6,552
6,717
4,090
7,711
1.1%
49Depreciation & amortization
2,108
2,105
1,955
1,946
2,206
3,601
3,398
3,417
4,071
5,592
5,167
9.4%
50Share-based compensation expense
322
311
329
311
308
330
341
401
431
530
494
4.4%
51Changes in working capital and other assets
(292)
216
6,914
645
(1,206)
(698)
(371)
(649)
(2,748)
1,278
(3,414)
27.9%
52Net cash flows from operating activities
9,077
10,354
11,177
11,296
9,150
10,497
9,261
9,721
8,471
11,490
9,958
0.9%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(649)
(837)
(664)
(738)
(618)
(608)
(880)
(936)
(1,112)
(1,096)
(1,858)
11.1%
54Purchases of investments / marketable securities
(25,977)
(28,094)
(33,607)
(18,741)
(9,394)
(8,477)
(8,900)
(2,587)
(1)
-
-
-
55Proceeds from maturities of marketable securities
21,556
20,417
30,414
33,768
29,390
6,978
13,234
1,218
1,673
-
-
-
56Other investing activities
(477)
(144)
(167)
50
(13,669)
(3,294)
(2,721)
(3,739)
(26,764)
50
(85)
(15.8)%
57Net cash flows from investing activities
(5,547)
(8,658)
(4,024)
14,339
5,709
(5,401)
733
(6,044)
(26,204)
(1,046)
(1,943)
(10)%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
(1,785)
(2,910)
(3,160)
(17,794)
(7,702)
(3,486)
(4,975)
(6,360)
-
(200)
-
-
59Dividends paid, net
(2,396)
(2,998)
(3,365)
(3,507)
(3,509)
(3,755)
(4,013)
(4,196)
(4,556)
(4,832)
(5,124)
7.9%
60Debt issuance (repayments), net
1,065
3,593
71
(1,121)
(4,514)
2,464
795
6,622
25,676
(4,259)
(5,683)
-
61Other financing activities
(1)
(284)
(140)
(68)
(42)
(90)
(78)
(103)
(72)
(124)
(52)
48.5%
62Net cash flows from financing activities
(3,117)
(2,599)
(6,594)
(22,490)
(15,767)
(4,867)
(8,271)
(4,037)
21,048
(9,415)
(10,859)
13.3%
63Increase (decrease) in cash and cash equivalents
413
(903)
559
3,145
(908)
229
1,723
(360)
3,315
1,029
(2,844)
-
64Cash and equivalents, ending balance
4,144
3,241
3,800
6,945
6,037
6,266
7,989
7,629
10,944
11,973
9,129
8.2%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
8,428
9,517
10,513
10,558
8,532
9,889
8,381
8,785
7,359
10,394
8,100
(0.4)%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Amgen Inc. (AMGN) financial statements and performance

Explore Amgen Inc. (AMGN) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.